<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: ABO-incompatible transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: ABO-incompatible transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: ABO-incompatible transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edmund Huang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley C Jordan, MD, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2628032627"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Blood type–incompatible kidney transplantation has been attempted since the earliest days of transplantation, but it was quickly learned that without desensitization prior to transplant, ABO incompatibility (ABOI) led to early rejection and allograft loss [<a href="#rid1">1</a>]. Later attempts at crossing the incompatible–blood type barrier relied on antibody reduction therapies including splenectomy, immunoadsorption, and/or plasmapheresis [<a href="#rid2">2</a>]. ABOI transplantation was not considered to be an acceptable method of transplantation until larger experiences, fueled by a shortage of deceased-donor kidneys from Japan, observed that patient and graft survival were comparable to ABO-compatible transplants [<a href="#rid3">3,4</a>]. Although ABOI transplants account for a large percentage of living-donor transplants in other parts of the world [<a href="#rid5">5,6</a>], they are infrequent in the United States and are generally relegated to transplant centers that are equipped with desensitization programs [<a href="#rid7">7</a>]. Nevertheless, because approximately 30 percent of donor and recipient pairs are predicted to be blood type incompatible, ABOI transplantation is a viable option for patients seeking kidney transplantation.</p><p>A general overview of ABOI in kidney transplantation and the techniques utilized to treat patients to overcome the ABO antibody barrier are presented in this topic review.</p><p class="headingAnchor" id="H1051498948"><span class="h1">OVERVIEW OF ABO BLOOD GROUP SYSTEM</span></p><p class="headingAnchor" id="H4022400493"><span class="h2">ABO antigens and antibodies</span><span class="headingEndMark"> — </span>The ABO blood group consists of four common categories (A, B, AB, and O), with types A and O most frequently found in the United States population. Antigen is expressed on red blood cells, lymphocytes, and platelets, as well as epithelial and endothelial cells. Formation of blood group antibodies, also referred to as isoagglutinins, occurs against those antigens not native to the host. Thus, antibodies to both A and B are found in an individual with blood type O, while an individual with blood type AB has no antibodies to A or B antigens. Given the distribution of blood group antigens in the United States, the waiting time on the deceased-donor allograft list is relatively longer for patients with blood group B or O when compared with A or AB [<a href="#rid8">8</a>].</p><p>In addition, individuals with blood type O tend to produce higher anti-A and anti-B isoagglutinin antibody levels than individuals with blood type A or B. Recipients with blood type O have a higher incidence of antibody-mediated rejection (ABMR) following ABOI transplantation [<a href="#rid9">9</a>] although graft survival does not differ among blood types [<a href="#rid7">7</a>]. </p><p>Blood group A consists of two subtypes, A1 and A2, or more appropriately "non-A1." Approximately 80 percent of individuals in the United States with blood group A express A1 [<a href="#rid10">10</a>]. The antigenic expression of A2 is quantitatively and qualitatively less than that of A1, and the overall immunogenic risk based on antigen expression alone is A1&gt;B&gt;A2 [<a href="#rid10">10</a>]. Given the lower immunogenic risk of the A2 antigen, donor A2 kidneys can generally be successfully transplanted into non-A recipients with low pretransplant anti-A titers without the use of desensitization [<a href="#rid11">11-16</a>]. (See <a class="local">'Blood type non-A1 (A2) donors'</a> below.)</p><p class="headingAnchor" id="H265358343"><span class="h2">Isoagglutinin antibody titers</span><span class="headingEndMark"> — </span>It was initially reported that higher baseline isoagglutinin antibody titers predispose to an increased risk of ABMR although subsequent data indicate the risk of ABMR may be more closely related to the isoagglutinin titer within the first one to two weeks posttransplant [<a href="#rid17">17</a>]. Although elevated isoagglutinin titers are generally observed during acute ABMR, the positive predictive value of elevated posttransplant titers beyond the first few weeks of transplant is poor, with high titers seen in otherwise stable ABOI recipients [<a href="#rid17">17</a>].</p><p>Institutions vary in how they measure and report isoagglutinin antibody titers [<a href="#rid18">18,19</a>], making it difficult to compare ABOI protocols and outcomes in the literature. The classic tube dilution method is most commonly used to report an immunoglobulin M (IgM) isoagglutinin titer (<a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> test) <strong>and</strong> a total isoagglutinin titer (indirect antiglobulin [Coombs] test), although direct IgG measurements can be made by pretreatment of plasma with dithiothreitol to inactivate IgM. The test should be considered semiquantitative because it depends on visual interpretation of the degree of agglutination and may be subject to interobserver variability. Thus, the reported result should be considered an approximation, and a titer reported at 1:128 could conceivably represent a titer of 1:64 to 1:256.</p><p>Other methods include column agglutination technology (gel), which is less time consuming but more costly than the tube dilution method. Titers obtained by the gel and tube dilution methods are generally comparable but can vary up to several standard dilutions from each other [<a href="#rid19">19,20</a>]. Improved assays, such as enzyme-linked immunosorbent assay (ELISA)-based technology, should assist in helping to define and standardize acceptable IgM and IgG isoagglutinin titers at baseline and in the peritransplant period. Although center-specific protocols vary, the total isoagglutinin antibody titer is generally reduced to at least 1:32 (and often to ≤1:8) before proceeding to transplantation as higher titers are associated with acute ABMR posttransplant [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3385965809"><span class="h1">TRANSPLANT OPTIONS FOR ABO INCOMPATIBILITY</span></p><p class="headingAnchor" id="H3714902629"><span class="h2">ABOI transplantation versus kidney paired donation</span><span class="headingEndMark"> — </span>For kidney transplant candidates who have an ABOI living donor and would like to utilize this donor, options include ABOI transplantation (if offered by the patient's transplant center) and kidney paired donation (KPD).</p><p class="bulletIndent1"><span class="glyph">●</span>ABOI living-donor transplantation requires a period of desensitization of the recipient prior to transplantation. Desensitization lowers anti-A/B antibody titers to a level that permits successful transplantation with commonly used induction and maintenance immunosuppression. (See <a class="local">'Approach to ABOI transplantation'</a> below and <a class="local">'Outcomes of ABOI transplantation'</a> below and <a class="local">'Complications of ABOI transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With a KPD program, willing participants can choose to exchange a donor to an alternate recipient with an ABO- or human leukocyte antigen (HLA)-incompatible donor [<a href="#rid22">22-24</a>]. This process avoids the need for desensitization and provides a living-donor allograft to each recipient. Both pairs must be in full agreement and have an understanding of the potential posttransplantation ramifications, as well as make a decision on whether or not the parties should remain anonymous to one another. KPD is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/115382.html" rel="external">"Kidney transplantation in adults: Kidney paired donation"</a>.)</p><p></p><p>Factors that influence the decision to pursue ABOI versus KPD include but are not limited to the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Center experience with incompatible transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recipient preference for their intended donor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The possibility that a donor with more favorable characteristics could result from KPD (eg, younger age, fewer medical complexities).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recipient blood type and allosensitization (calculated panel reactive antibodies [cPRA]) and their impact on the likelihood and timing of being matched to a donor in a KPD program. Data from both the National Kidney Registry (NKR) and the Alliance for Paired Donation (APD) indicate that highly sensitized patients and/or those with blood type O are less likely to have success with KPD [<a href="#rid25">25-27</a>]. In NKR, 43 percent of patients with blood type O overall remain unmatched within one year of registration [<a href="#rid27">27</a>]. When O blood type is combined with cPRA ≥98 percent, nearly all candidates (90 percent) remain waiting for transplant at one year after registration [<a href="#rid26">26</a>], suggesting that ABOI transplant should be strongly considered for these patients rather than KPD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whether vascular access for plasmapheresis needs to be placed for ABOI desensitization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The recipient's ability to tolerate the higher intensity of immunosuppression required for ABOI transplantation.</p><p></p><p>These are generally complex decisions that involve guidance from the transplant center, but ultimately, the patient should be allowed to decide which option best fits their preference.</p><p class="headingAnchor" id="H46649981"><span class="h2">Blood type non-A1 (A2) donors</span><span class="headingEndMark"> — </span>Another option for candidates with blood type B or O is transplantation with a kidney from a blood type non-A1 (A2) donor. Approximately 20 percent of the blood type A population is subtype A2. These donors may come from either living or deceased donors. Donors with this subtype are blood type A, but their red blood cells do not agglutinate with the anti-A1 lectin antiserum used to subtype for A1. For all practical purposes, these donors are considered subtype A2 although there are other non-A1 phenotypes that have weaker antigenic expression than subtypes A1 and A2 [<a href="#rid28">28</a>]. Lectin agglutination accurately subtypes for A1 when strongly reactive and for A2 when nonreactive. Weakly reactive lectin agglutination is typically subtyped as A1 although ABO genotyping indicates that a small percentage of these are indeed A2 [<a href="#rid29">29</a>]. These misclassified donors represent potential missed opportunities for transplantation for blood group incompatible recipients that need to be studied further. (See <a class="local">'ABO antigens and antibodies'</a> above.)</p><p>Antigenic expression of the A carbohydrate antigen N acetylgalactosamine is reduced in the kidney cortex and endothelial surfaces of A2 donor kidneys, thereby making these kidneys inherently less antigenic to recipients with incompatible blood types. The ability to successfully transplant A2 donor kidneys <strong>without</strong> pretransplant desensitization was recognized early on in the history of ABOI transplantation, in the 1980s [<a href="#rid30">30</a>], and later confirmed by several groups in the 1990s and early 2000s [<a href="#rid14">14,31,32</a>]. Because of the weaker immunogenicity and paucity of expression of A2 in donor kidneys, ABOI transplantation can be performed when pretransplant desensitization is not logistically feasible, such as in deceased-donor kidney transplantation.</p><p>Given the longer waiting times of blood type B and O candidates, the allocation of A2 kidneys to select blood group B and O candidates has been studied, demonstrating significantly reduced wait times to transplant with no significant increase in graft loss or death [<a href="#rid33">33,34</a>]. The Organ Procurement and Transplant Network (OPTN) kidney allocation system implemented in 2014 permits allocation of A2 and A2B kidneys to blood group B candidates meeting center-specific criteria including prespecified, low anti-A titers [<a href="#rid35">35</a>]. Acceptance of A2 kidneys is optional for the candidate.</p><p>A low baseline anti-A blood group titer is a <strong>prerequisite</strong> for ABOI transplantation from an A2 donor. It is our opinion that both anti-A IgG and IgM should be low when undergoing incompatible transplantation from an A2 donor, based upon data showing an association between baseline total anti-A (IgM and IgG) titers and rejection [<a href="#rid32">32,36</a>]. Acceptable thresholds for baseline anti-A titers vary across institutions. Most reports describe an anti-A titer of ≤1:8 [<a href="#rid13">13,15,37</a>], although there are reports of successful transplantation with higher titers [<a href="#rid14">14,38</a>].</p><p>At our institution, we use a baseline anti-A2 titer of ≤1:16 as our threshold [<a href="#rid39">39</a>] and register all consenting blood type B recipients with an anti-A2 titer ≤1:16 for non-A1 donors. We recheck the anti-A2 titer preoperatively for deceased-donor kidney transplant and proceed if the titer remains ≤1:16. Patients receive the same induction and maintenance immunosuppression as that used for recipients of ABO-compatible transplants. We follow the same monitoring protocol that we use for ABOI transplants. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a> and <a class="local">'Monitoring after transplantation'</a> below.) </p><p class="headingAnchor" id="H1661263276"><span class="h1">APPROACH TO ABOI TRANSPLANTATION</span><span class="headingEndMark"> — </span>Approaches to ABOI transplantation vary among transplant centers and are usually institution specific. The approach used at our centers is described below.</p><p class="headingAnchor" id="H3028739930"><span class="h2">Patient eligibility</span><span class="headingEndMark"> — </span>ABOI transplant candidates must meet center-specific general transplant candidate selection criteria in addition to ABOI-specific criteria. (See  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a>.)</p><p>There are no established ABOI-specific selection criteria for recipients, and criteria vary among transplant centers. At our institution, patients must satisfy the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient must have an initial ABO isoagglutinin titer of ≤1:256 for both IgG and IgM using the tube dilution method. Some institutions do not employ criteria for baseline isoagglutinin titer and rely only on the antibody titer achieved after desensitization to determine suitability for ABOI transplantation. Antibody titers vary across institutions, and a given titer at one center may not equate with one obtained from a different program. (See <a class="local">'Isoagglutinin antibody titers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient must be willing to undergo ABOI transplantation and all the therapies associated with ABOI transplantation. A low level of anti-human leukocyte antigen (HLA) donor-specific antibodies (DSAs) may also be present in some patients since desensitization and immunosuppressive regimens are similar.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient must have prior authorization from their insurance company for all therapies associated with ABOI transplantation.</p><p></p><p class="headingAnchor" id="H3902381980"><span class="h2">Pretransplant ABO desensitization</span></p><p class="headingAnchor" id="H2095736352"><span class="h3">Overview of desensitization</span><span class="headingEndMark"> — </span>The overall goals and purpose of ABO desensitization are to lower the anti-A/B antibody titers to a level that is not associated with immediate antibody injury to the allograft and allows successful transplantation with commonly used induction and maintenance immunosuppression. </p><p>Although there is no uniformly accepted ABO desensitization protocol, most commonly used protocols employ a combination of the following strategies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Removal of circulating ABO antibodies </strong>– The reduction of circulating anti-A/B antibody levels to predesignated target titers is a key component of most ABO desensitization protocols. The two most commonly used methods of antibody removal are plasmapheresis and immunoadsorption, with the goal of achieving titers ≤1:8 to 1:32, depending on center practice. The number of treatment sessions is generally determined by the baseline anti-A/B antibody titer [<a href="#rid40">40-43</a>]. Immunoadsorption is not available in the United States but is frequently used in Europe. (See <a class="local">'Isoagglutinin antibody titers'</a> above and  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p></p><p class="bulletIndent1">Plasmapheresis is associated with an increased risk of bleeding complications [<a href="#rid44">44</a>]. Bleeding episodes are usually associated with significantly lower values of fibrinogen, platelets, prothrombin time, and hemoglobin levels. Thus, allowing fibrinogen levels to return to the normal range after plasmapheresis or repleting with cryoprecipitate is likely to reduce or prevent risk for bleeding at the time of ABOI transplantation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulation </strong>– Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) is administered by many transplant centers prior to ABOI transplantation to replace immunoglobulins that are removed with plasmapheresis or immunoadsorption. In addition, IVIG may also block Fc receptors to prevent a rebound in anti-A/B antibody titers when the plasma cells have unbound receptors and, therefore, are stimulated to make more antibody. IVIG may also have immunoregulatory properties and likely reduces circulating IgG when administered in high doses by saturating the Fc neonatal receptor that normally protects IgG from lysosomal degradation [<a href="#rid45">45</a>]. It should be noted, however, that IVIG products may contain detectable anti-A and anti-B isoagglutinins [<a href="#rid41">41,46</a>], which should be considered if high-dose IVIG is administered. In our own practice, we have observed hemolysis in some patients given high-dose IVIG products [<a href="#rid47">47</a>]. This has resulted in IVIG manufacturers adding procedures to remove isoagglutinins from IVIG products that are labeled Iso-low and are associated with lower risk for hemolysis [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell depletion </strong>– Therapies targeting B cells are used in desensitization protocols because B cells are the precursors for plasma cells that produce the anti-A/B antibodies. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, a humanized mouse monoclonal antibody that targets CD20 (expressed on the majority of B cells), is the most commonly used agent and has replaced splenectomy, which was a component of the earliest successful ABOI protocols but is associated with greater surgical risks and longer-term morbidity [<a href="#rid49">49-52</a>].</p><p></p><p class="headingAnchor" id="H94528959"><span class="h3">Our approach to desensitization</span><span class="headingEndMark"> — </span>For patients who will undergo ABOI transplantation, we suggest pretransplant desensitization with the combination of plasmapheresis (or immunoadsorption, where available), <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than plasmapheresis (or immunoadsorption) and IVIG alone. However, clinical practice varies among transplant centers that perform ABOI transplantation, and protocols also vary geographically. As an example, while plasmapheresis is the preferred antibody removal strategy in the United States, immunoadsorption is more commonly used in Europe.</p><p>At our centers, desensitization begins one month prior to the scheduled living-donor transplant surgery. Transplantation is performed when the isoagglutinin antibody titer is ≤1:8.</p><p class="bulletIndent1"><span class="glyph">●</span>At <strong>four weeks </strong>prior to the scheduled transplant surgery date, we administer a single dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> 500 mg. The optimal dose of rituximab is unclear, and some centers have reported successful outcomes with lower doses (eg, 100 to 200 mg) [<a href="#rid53">53</a>]. We premedicate for rituximab with intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 125 mg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> 650 mg given orally, and <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> 50 mg given orally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At <strong>four weeks</strong> prior to the scheduled transplant surgery date, we start immunosuppression by administering oral enteric-coated <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium (EC-MPS) 360 mg twice daily (or mycophenolate mofetil [MMF] 500 mg twice daily). (See <a class="local">'Transplant immunosuppression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At <strong>two weeks</strong> prior to the scheduled transplant surgery date, we initiate plasmapheresis to achieve a goal isoagglutinin titer of ≤1:8, for both IgM (<a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) and IgG (Coombs). We perform alternate-day plasmapheresis (usually on Monday, Wednesday, and Friday) for four to five sessions, depending on the initial isoagglutinin titer. Per center protocol, we generally perform plasmapheresis regardless of baseline isoagglutinin titer, even if the titer is already low at baseline. We perform one plasma volume exchange using 5 percent albumin for each plasmapheresis session. </p><p></p><p class="bulletIndent1">Some centers have reported successful ABOI transplantation without plasmapheresis when the baseline titer is ≤1:16 [<a href="#rid43">43</a>]. However, severe rejections have been seen in patients with acceptable anti-A/B titers at baseline [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1">In general, the titer can be expected to decrease by one dilution with each session of plasmapheresis. This can be used to estimate the number of plasmapheresis sessions necessary to achieve the target titer. As an example, if the starting titer is 1:128, it will take three plasmapheresis sessions to achieve a titer of 1:16 (1:128 to 1:64, 1:64 to 1:32, and 1:32 to 1:16).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The final plasmapheresis session is generally performed three to four days before the transplant date. We use 5 percent albumin for replacement. However, when plasmapheresis is performed immediately before or after surgery, replacement with blood type AB or donor-specific plasma is preferable to albumin, to minimize bleeding complications while avoiding passive transfer of relevant blood group antibodies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immediately following the final plasmapheresis session, we give <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> 2 g/kg (maximum dose 140 g). The optimal dose of IVIG is uncertain, and some transplant centers administer a lower dose (500 mg/kg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upon completion of this desensitization protocol, transplant surgery can be performed.</p><p></p><p>There is no high-quality evidence in the form of randomized trials to guide the optimal approach to ABO desensitization. Evidence in support of our approach comes primarily from several observational studies showing that a combined approach involving antibody removal (either with plasmapheresis or immunoadsorption), immunomodulation with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, and B cell depletion (with splenectomy or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) is associated with successful ABOI transplantation and overall good patient and graft outcomes [<a href="#rid40">40,42,53,55-61</a>] (see <a class="local">'Patient and graft survival'</a> below). From these collective data, the following points can be highlighted:</p><p class="bulletIndent1"><span class="glyph">●</span>Both plasmapheresis (conventional plasmapheresis or double-filtration plasmapheresis) and immunoadsorption have been shown to effectively reduce anti-A/B antibody titers prior to ABOI transplantation [<a href="#rid40">40,42,53,55-61</a>]. Early studies found that plasmapheresis alone was not sufficient, and the addition of B cell depletion was required for successful transplantation [<a href="#rid50">50,62</a>]. There are no trials directly comparing the efficacy and safety of these antibody removal modalities. One observational study found a higher risk of postoperative bleeding with plasmapheresis compared with immunoadsorption (13 versus 2 percent) [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> has been a widely used component of desensitization strategies although there are no studies directly comparing protocols with or without the use of IVIG. Immunoadsorption-based and DFPP-based protocols without the use of IVIG have been reported, with no apparent adverse effect on outcomes [<a href="#rid42">42,59</a>]. There are no studies comparing different doses of IVIG for ABO desensitization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no randomized trials directly comparing <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and splenectomy. A systematic review comparing a rituximab-based with a splenectomy-based protocol for ABOI found no significant difference overall in patient survival, graft survival, or allograft function, with single studies demonstrating lower isoagglutinin titers and lower rates of antibody-mediated rejection (ABMR) in the rituximab groups [<a href="#rid63">63</a>]. In a meta-analysis using patient-level data from observational studies, five-year graft survival was 91 percent among patients who received rituximab and 80 percent for those who underwent splenectomy prior to transplantation [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal dose of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> used for ABOI transplantation is unclear. One small Japanese study found that single doses of 35 mg/m<sup>2</sup> (approximately 100 mg as a single dose) or higher eliminated detectable splenic B cells [<a href="#rid65">65</a>]. Excellent long-term outcomes have been reported with rituximab 100 mg [<a href="#rid66">66</a>], 200 mg [<a href="#rid67">67</a>], 500 mg [<a href="#rid68">68</a>], and 375 mg/m<sup>2</sup> [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Successful ABOI transplantation has been reported without anti-CD20 therapy [<a href="#rid43">43</a>], but this practice is not universally accepted. Some reports of ABOI transplants without anti-CD20 therapy have employed posttransplant plasmapheresis for at least two weeks to keep the anti-blood group titer ≤1:16 [<a href="#rid69">69</a>]. This approach is both labor and resource intensive, and there is additional concern that the posttransplant anti-blood group antibody titer may not be a reliable predictor for ABMR [<a href="#rid70">70</a>]. In a case report of two patients who underwent ABOI transplant without desensitization, acute kidney injury was observed before increases in antibody titer, and, ultimately, both patients required allograft nephrectomy within two weeks of transplant [<a href="#rid54">54</a>]. In addition, excessive posttransplant plasmapheresis may increase bleeding and infection risk in these patients.</p><p></p><p class="headingAnchor" id="H3809641418"><span class="h2">Transplant immunosuppression</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction immunosuppression </strong>– The optimal induction immunosuppressive therapy for ABOI transplantation is not known. Our approach to induction immunosuppression in ABOI recipients is the same as that for patients undergoing ABO-compatible transplantation, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Approach to induction therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance immunosuppression </strong>– In recipients of an ABOI kidney transplant, we administer a triple therapy maintenance immunosuppression regimen that includes a calcineurin inhibitor (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>), and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. This combination is similar to the initial maintenance immunosuppression used in most ABO-compatible kidney transplant recipients, with the exception that mycophenolate is started four weeks before transplant rather than on the day of transplant surgery. (See <a class="local">'Our approach to desensitization'</a> above and  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1">In ABOI recipients, we target higher whole-blood <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> levels compared with ABO-compatible transplant recipients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>8 to 12 ng/mL for the first month after transplantation</p><p class="bulletIndent2"><span class="glyph">•</span>5 to 10 ng/mL for subsequent months</p><p></p><p class="headingAnchor" id="H573093229"><span class="h2">Infection prophylaxis</span><span class="headingEndMark"> — </span>In all ABOI recipients, we administer antimicrobial and antiviral prophylaxis with a regimen that is identical to that administered to recipients of an ABO-compatible transplant. This includes prophylaxis against <em>Pneumocystis</em> pneumonia (PJP) and cytomegalovirus (CMV) infection and disease. We also administer antifungal prophylaxis although this practice may vary by transplant center. In addition, at our institution, we require meningococcal vaccination for all patients undergoing desensitization in the event they need complement inhibitor therapy after transplant. We vaccinate against serogroups A, C, W, and Y and against serogroup B. </p><p>A detailed discussion of the different prophylactic regimens and vaccinations is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Pneumocystis pneumonia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/105281.html" rel="external">"Prevention of cytomegalovirus disease in kidney transplant recipients", section on 'Our approach'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Antifungal prophylaxis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>.)</p><p></p><p class="headingAnchor" id="H3197171313"><span class="h2">Monitoring after transplantation</span><span class="headingEndMark"> — </span>Following ABO desensitization and transplantation, patients are monitored using a similar approach as that used in recipients of ABO-compatible transplants. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'</a>.)</p><p>In addition, we monitor isoagglutinin titers daily while the patient is in the hospital and two times per week for the first month posttransplant. In patients with a posttransplant isoagglutinin titer ≥1:16, a kidney biopsy and/or preemptive plasmapheresis should be performed, particularly if there is evidence of graft dysfunction (eg, delayed/slow graft function or rising serum creatinine). We do <strong>not</strong> routinely perform protocol plasmapheresis posttransplant.</p><p>We do not perform protocol kidney allograft biopsies in our center. Other transplant centers vary in the use and timing of protocol kidney allograft biopsies. The C4d result must be interpreted with other histologic parameters as well as the clinical scenario in order to distinguish immunologic accommodation versus ABMR. (See <a class="local">'Immunologic accommodation'</a> below and  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p class="headingAnchor" id="H4101193479"><span class="h1">IMMUNOLOGIC ACCOMMODATION</span><span class="headingEndMark"> — </span>When exposed to a low titer of anti-A/B antibodies, the kidney allograft develops the ability to resist complement-mediated damage approximately two weeks after transplantation. This phenomenon, known as immunologic accommodation, is characterized by the presence of detectable isoagglutinin titers, AB endothelial antigen expression, and positive peritubular capillary (PTC) C4d staining despite the absence of any histologic evidence of antibody-mediated rejection (ABMR) [<a href="#rid71">71</a>]. The presence of positive PTC C4d staining in ABOI transplantation has been described by others [<a href="#rid31">31,72-74</a>] and appears to have a different connotation than when seen in the setting of ABMR secondary to human leukocyte antigen (HLA) incompatibility.</p><p>Based upon these findings, we do not initiate treatment for ABMR based upon an isolated finding of positive PTC C4d staining in ABOI transplantation. When graft dysfunction secondary to ABMR is present in the setting of ABOI transplantation, PTC C4d is likely to be positive, but histologic manifestations associated with ABMR (ie, peritubular capillaritis and/or glomerulitis) are also likely to be present [<a href="#rid31">31</a>].</p><p>In one study, histologic changes and C4d staining were examined on surveillance biopsies performed one and five years posttransplant in 73 ABOI, 102 crossmatch-positive, and 652 conventional kidney transplants [<a href="#rid75">75</a>]. At five years, biopsies in ABOI kidneys showed significantly higher rates of C4d deposition compared with crossmatch-positive kidneys (78 versus 19 percent), yet death-censored graft survival was superior (80 versus 71 percent). In addition, estimated glomerular filtration rate (eGFR) in surviving grafts was superior in ABOI compared with crossmatch-positive transplants (51 versus 44 mL/min) and closely resembled that of conventional transplants (48.5 mL/min).</p><p>Another analysis found that C4d-positive staining was present in 80 percent of protocol ABOI allograft biopsies and in 58 percent of ABOI biopsies performed for graft dysfunction [<a href="#rid73">73</a>]. There was no correlation between this finding and histologic evidence of ABMR or graft injury. </p><p class="headingAnchor" id="H1424529280"><span class="h1">OUTCOMES OF ABOI TRANSPLANTATION</span></p><p class="headingAnchor" id="H2797630487"><span class="h2">Patient and graft survival</span><span class="headingEndMark"> — </span>Compared with ABO-compatible transplantation, ABOI kidney transplantation has been associated with lower graft and patient survival within the first three years posttransplant. However, longer-term graft and patient survival rates after ABOI transplantation appear to be comparable to those after ABO-compatible transplantation [<a href="#rid76">76,77</a>]. The best data come from a 2019 meta-analysis of 40 observational studies that compared patient and graft outcomes among 7098 ABOI kidney transplant recipients and 57,965 ABO-compatible recipients [<a href="#rid76">76</a>]. The following findings were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with ABO-compatible transplantation, ABOI transplantation was associated with a higher risk of mortality at one (odds ratio [OR] 2.17, 95% CI 1.63-2.90), three (OR 1.89, 95% CI 1.46-2.45), and five (OR 1.47, 95% CI 1.08-2.00) years posttransplant but not at eight or more years posttransplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Death-censored graft survival was lower for ABOI transplant recipients than for ABO-compatible transplant recipients at one (OR 2.52, 95% CI 1.80-3.54) and three (OR 1.59, 95% CI 1.15-2.18) years posttransplant but was comparable between the two groups after five years posttransplant.</p><p></p><p>Outcomes of transplantation across both ABOI and human leukocyte antigen (HLA) barriers are inferior to those of ABOI transplantation, with increased incidence of early and late acute T cell-mediated rejection and antibody-mediated rejection (ABMR) [<a href="#rid21">21,78</a>].</p><p class="headingAnchor" id="H3706344628"><span class="h2">Cost of ABOI transplantation</span><span class="headingEndMark"> — </span>While multicenter studies have established ABOI live-donor kidney transplantation as a clinically effective method to expand access to transplantation in Japan and Europe, ABOI transplants remain infrequent in the United States due to concerns for high costs of the necessary preconditioning and posttransplant care. In a study examining the United States Renal Data System records for Medicare-insured, live-donor kidney transplant recipients in 2000 to 2012, compared with recipients of ABO-compatible transplants, ABOI recipients experienced modest reductions in three-year patient and graft survival [<a href="#rid79">79</a>]. The average total costs of ABOI transplant hospitalizations were USD $65,080, compared with USD $36,752 and USD $32,039 for A2 incompatible and ABO-compatible transplant hospitalizations, respectively. Adjusted marginal costs of ABOI remained significantly higher during year 1 (USD $25,044), year 2 (USD $10,496), and year 3 (USD $7307) posttransplant. These findings support broader use of ABOI transplantation to expand access to transplantation, particularly for blood group O candidates. While more expensive than ABO-compatible transplantation and associated with modest reductions in outcomes, the increases in total spending are justified by avoiding long-term dialysis and its associated morbidity and costs.</p><p class="headingAnchor" id="H2924681438"><span class="h1">COMPLICATIONS OF ABOI TRANSPLANTATION</span></p><p class="headingAnchor" id="H2797390341"><span class="h2">Rejection</span><span class="headingEndMark"> — </span>ABOI transplantation has been associated with a three- to fourfold increased risk of antibody-mediated rejection compared with ABO-compatible transplantation [<a href="#rid76">76,77</a>]. The incidence of active antibody-mediated rejection (ABMR) after ABOI transplantation has been reported in the range of 10 to 30 percent. ABMR most commonly occurs within the first two weeks after ABOI transplantation.</p><p>The diagnosis and treatment of ABMR are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a> and  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p class="headingAnchor" id="H3254225252"><span class="h2">Surgical complications</span><span class="headingEndMark"> — </span>Higher rates of perioperative bleeding have been observed in recipients of ABOI transplants, likely due to the loss of clotting factors due to the plasmapheresis procedure [<a href="#rid76">76,80-83</a>]. Patients who require a perioperative blood transfusion should receive recipient ABO-type leukocyte-depleted packed red blood cells as indicated.</p><p>In addition, a higher rate of lymphoceles (19 to 50 percent) has been reported in ABOI transplant recipients, compared with ABO-compatible transplant recipients [<a href="#rid57">57,76,80,84,85</a>]. The reason for this is unclear although some have attributed it to the early initiation of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H3385742387"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Compared with ABO-compatible recipients, recipients of ABOI kidneys may be at higher risk for infectious complications. One meta-analysis found that ABOI transplantation was associated with a higher risk of sepsis (odds ratio [OR] 2.14, 95% CI 1.37-3.33) compared with ABO-compatible transplantation [<a href="#rid76">76</a>]. Individual studies have also reported that recipients of ABOI kidneys may be at higher risk for pneumonia, urinary tract infections or pyelonephritis, wound infection, and BK polyomavirus nephropathy [<a href="#rid42">42,44,84,87</a>]. </p><p class="headingAnchor" id="H2032835666"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>ABOI recipients do not have an increased risk of malignancy compared with ABO-compatible transplant patients. In a study of 318 ABOI recipients, seven cancers were diagnosed a median of 3.6 years after transplantation [<a href="#rid88">88</a>]. There was no significant difference in cancer risk between ABOI recipients and matched ABO-compatible controls. Similar findings were reported in another multicenter study of 1420 ABOI transplant recipients [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p class="headingAnchor" id="H3361608360"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H604541874"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplant options for ABO incompatibility </strong>– Approximately 30 percent of donor and recipient pairs are predicted to be blood type incompatible.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For kidney transplant candidates who have an ABO-incompatible (ABOI) living donor and would like to utilize this donor, options include ABOI transplantation (if offered by the patient's transplant center) and kidney paired donation (KPD). ABOI transplantation requires desensitization prior to transplant to lower the anti-A/B antibody titers to a level that is not associated with immediate antibody injury to the allograft and allows successful transplantation with commonly used induction and maintenance immunosuppressive regimens. (See <a class="local">'ABOI transplantation versus kidney paired donation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another option for candidates with blood type B or O is transplantation with a kidney from a blood type non-A1 (A2) donor. Because of the weaker immunogenicity and paucity of expression of the A2 antigen in donor kidneys, transplantation can be performed without pretransplant desensitization. In the United States, the kidney allocation system allows allocation of non-A1 (A2) deceased donors to blood type B recipients. (See <a class="local">'Blood type non-A1 (A2) donors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to ABO-incompatible transplantation </strong>– Approaches to ABOI transplantation vary among transplant centers. Our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pretransplant desensitization</strong> – For patients who will undergo ABOI transplantation, we suggest pretransplant desensitization with the combination of plasmapheresis (or immunoadsorption, where available), intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than plasmapheresis (or immunoadsorption) and IVIG alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Our protocol is detailed above. (See <a class="local">'Our approach to desensitization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transplant immunosuppression </strong>– Our approach to induction and maintenance immunosuppression in ABOI recipients is similar to that for patients undergoing ABO-compatible transplantation, with the exception that <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> is started four weeks before transplant rather than on the day of transplant surgery. (See <a class="local">'Transplant immunosuppression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection prophylaxis</strong> – In all ABOI recipients, we administer antimicrobial and antiviral prophylaxis with a regimen that is identical to that administered to recipients of an ABO-compatible transplant. (See <a class="local">'Infection prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Posttransplant monitoring </strong>– Following transplantation, patients are monitored using a similar approach as that used in recipients of ABO-compatible transplants. In addition, we monitor isoagglutinin titers daily while the patient is in the hospital and two times per week for the first month posttransplant. In patients with a posttransplant isoagglutinin titer ≥1:16, a kidney biopsy and/or preemptive plasmapheresis should be performed, particularly if there is evidence of graft dysfunction. (See <a class="local">'Monitoring after transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– Compared with ABO-compatible transplantation, ABOI kidney transplantation has been associated with lower graft and patient survival within the first three years posttransplant. However, longer-term graft and patient survival rates appear to be comparable. (See <a class="local">'Outcomes of ABOI transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Complications of ABOI transplantation include higher risks of antibody-mediated rejection (ABMR), perioperative bleeding and lymphoceles, and infectious complications. (See <a class="local">'Complications of ABOI transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H1110475114"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Christina Klein, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">HUME DM, MAGEE JH, KAUFFMAN HM Jr, et al. RENAL HOMOTRANSPLANTATION IN MAN IN MODIFIED RECIPIENTS. Ann Surg 1963; 158:608.</a></li><li><a class="nounderline abstract_t">Cardella CJ, Pei Y, Brady HR. ABO blood group incompatible kidney transplantation: a case report and review of the literature. Clin Nephrol 1987; 28:295.</a></li><li><a class="nounderline abstract_t">Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65:224.</a></li><li><a class="nounderline abstract_t">Ota K, Takahashi K, Agishi T, et al. Multicentre trial of ABO-incompatible kidney transplantation. Japanese Biosynsorb ABO-incompatible kidney transplant study group. Transpl Int 1992; 5 Suppl 1:S40.</a></li><li><a class="nounderline abstract_t">Langhorst C, Ganner A, Schneider J, et al. Long-term Follow-up of ABO-Incompatible Kidney Transplantation in Freiburg, Germany: A Single-Center Outcome Report. Transplant Proc 2021; 53:848.</a></li><li><a class="nounderline abstract_t">Yagisawa T, Mieno M, Yoshimura N, et al. Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry Committee, Japanese Society for Clinical Renal Transplantation and the Japan Society for Transplantation. Ren Replace Ther 2016; 2.</a></li><li><a class="nounderline abstract_t">Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012; 93:603.</a></li><li><a class="nounderline abstract_t">Lentine KL, Smith JM, Hart A, et al. OPTN/SRTR 2020 Annual Data Report: Kidney. Am J Transplant 2022; 22 Suppl 2:21.</a></li><li><a class="nounderline abstract_t">Toki D, Ishida H, Horita S, et al. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 2009; 88:1186.</a></li><li><a class="nounderline abstract_t">Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42:88.</a></li><li><a class="nounderline abstract_t">Norman DJ, Prather JC, Alkhunaizi AM, et al. Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade. Transplant Proc 2001; 33:3327.</a></li><li><a class="nounderline abstract_t">Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635.</a></li><li><a class="nounderline abstract_t">Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65:256.</a></li><li><a class="nounderline abstract_t">Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001; 1:296.</a></li><li><a class="nounderline abstract_t">Bryan CF, Winklhofer FT, Murillo D, et al. Improving access to kidney transplantation without decreasing graft survival: long-term outcomes of blood group A2/A2B deceased donor kidneys in B recipients. Transplantation 2005; 80:75.</a></li><li><a class="nounderline abstract_t">Forbes RC, Feurer ID, Shaffer D. A2 incompatible kidney transplantation does not adversely affect graft or patient survival. Clin Transplant 2016; 30:589.</a></li><li><a class="nounderline abstract_t">Tobian AA, Shirey RS, Montgomery RA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10:1247.</a></li><li><a class="nounderline abstract_t">Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 2006; 13:136.</a></li><li><a class="nounderline abstract_t">Kumlien G, Wilpert J, Säfwenberg J, Tydén G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007; 84:S17.</a></li><li><a class="nounderline abstract_t">Shirey RS, Cai W, Montgomery RA, et al. Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. Transfusion 2010; 50:631.</a></li><li><a class="nounderline abstract_t">Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9:567.</a></li><li><a class="nounderline abstract_t">Delmonico FL, Morrissey PE, Lipkowitz GS, et al. Donor kidney exchanges. Am J Transplant 2004; 4:1628.</a></li><li><a class="nounderline abstract_t">de Klerk M, Keizer KM, Claas FH, et al. The Dutch national living donor kidney exchange program. Am J Transplant 2005; 5:2302.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Allen JE, Fuggle SV, et al. Early experience of paired living kidney donation in the United kingdom. Transplantation 2008; 86:1672.</a></li><li><a class="nounderline abstract_t">Stepkowski SM, Mierzejewska B, Fumo D, et al. The 6-year clinical outcomes for patients registered in a multiregional United States Kidney Paired Donation program - a retrospective study. Transpl Int 2019; 32:839.</a></li><li><a class="nounderline abstract_t">Holscher CM, Jackson K, Chow EKH, et al. Kidney exchange match rates in a large multicenter clearinghouse. Am J Transplant 2018; 18:1510.</a></li><li><a class="nounderline abstract_t">Holscher CM, Jackson K, Thomas AG, et al. Temporal changes in the composition of a large multicenter kidney exchange clearinghouse: Do the hard-to-match accumulate? Am J Transplant 2018; 18:2791.</a></li><li><a class="nounderline abstract_t">Svensson L, Bindila L, Angström J, et al. The structural basis of blood group A-related glycolipids in an A3 red cell phenotype and a potential explanation to a serological phenomenon. Glycobiology 2011; 21:162.</a></li><li><a class="nounderline abstract_t">Joseph A, Murray CJ, Novikov ND, et al. ABO Genotyping finds more A2 to B kidney transplant opportunities than lectin-based subtyping. Am J Transplant 2023; 23:512.</a></li><li><a class="nounderline abstract_t">Breimer ME, Brynger H, Le Pendu J, et al. Blood group ABO-incompatible kidney transplantation biochemical and immunochemical studies of blood group A glycolipid antigens in human kidney and characterization of the antibody response (antigen specificity and antibody class) in O recipients receiving A2 grafts. Transplant Proc 1987; 19:226.</a></li><li><a class="nounderline abstract_t">Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971.</a></li><li><a class="nounderline abstract_t">Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67:1319.</a></li><li><a class="nounderline abstract_t">Hurst FP, Sajjad I, Elster EA, et al. Transplantation of A2 kidneys into B and O recipients leads to reduction in waiting time: USRDS experience. Transplantation 2010; 89:1396.</a></li><li><a class="nounderline abstract_t">Bryan CF, Nelson PW, Shield CF 3rd, et al. Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate. Clin Transpl 2004; :127.</a></li><li class="breakAll">http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf.</li><li><a class="nounderline abstract_t">Tierney J, Shaffer D. Transplantation of ABO A2 kidneys into O recipients: do IgM anti-A1 titers matter? Clin Transplant 2015; 29:379.</a></li><li><a class="nounderline abstract_t">Williams WW, Cherikh WS, Young CJ, et al. First Report on the OPTN National Variance: Allocation of A2 /A2 B Deceased Donor Kidneys to Blood Group B Increases Minority Transplantation. Am J Transplant 2015; 15:3134.</a></li><li><a class="nounderline abstract_t">Fidler ME, Gloor JM, Lager DJ, et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4:101.</a></li><li><a class="nounderline abstract_t">Azzi Y, Nair G, Loarte-Campos P, et al. A Safe Anti-A2 Titer for a Successful A2 Incompatible Kidney Transplantation: A Single-center Experience and Review of the Literature. Transplant Direct 2021; 7:e662.</a></li><li><a class="nounderline abstract_t">Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246.</a></li><li><a class="nounderline abstract_t">Morath C, Becker LE, Leo A, et al. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012; 93:827.</a></li><li><a class="nounderline abstract_t">Barnett AN, Manook M, Nagendran M, et al. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int 2014; 27:187.</a></li><li><a class="nounderline abstract_t">Masterson R, Hughes P, Walker RG, et al. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone. Am J Transplant 2014; 14:2807.</a></li><li><a class="nounderline abstract_t">Lentine KL, Axelrod D, Klein C, et al. Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients. Transplantation 2014; 98:54.</a></li><li><a class="nounderline abstract_t">Jordan SC, Ammerman N, Vo A. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics. Transplantation 2020; 104:17.</a></li><li><a class="nounderline abstract_t">Staley EM, Carruba SS, Manning M, et al. Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation. Am J Transplant 2016; 16:2483.</a></li><li><a class="nounderline abstract_t">Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993.</a></li><li><a class="nounderline abstract_t">Cen SY, Branch DR. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis. Transfusion 2020; 60:250.</a></li><li><a class="nounderline abstract_t">Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985; 28:231.</a></li><li><a class="nounderline abstract_t">Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19:4538.</a></li><li><a class="nounderline abstract_t">Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 70:681.</a></li><li><a class="nounderline abstract_t">Gloor JM, Lager DJ, Fidler ME, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572.</a></li><li><a class="nounderline abstract_t">Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91:853.</a></li><li><a class="nounderline abstract_t">Krishnan N, Coates R, Daga S, et al. ABO-incompatible renal transplantation without antibody removal using conventional immunosuppression alone. Am J Transplant 2015; 15:1728.</a></li><li><a class="nounderline abstract_t">Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11:1016.</a></li><li><a class="nounderline abstract_t">Tydén G, Donauer J, Wadström J, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83:1153.</a></li><li><a class="nounderline abstract_t">Zschiedrich S, Jänigen B, Dimova D, et al. One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience. Nephrol Dial Transplant 2016; 31:663.</a></li><li><a class="nounderline abstract_t">Genberg H, Kumlien G, Wennberg L, Tyden G. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2011; 26:2394.</a></li><li><a class="nounderline abstract_t">Schiesser M, Steinemann DC, Hadaya K, et al. The Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient: The Swiss Experience. Transplantation 2015; 99:1030.</a></li><li><a class="nounderline abstract_t">Bentall A, R Barnett AN, Braitch M, et al. Clinical outcomes with ABO antibody titer variability in a multicenter study of ABO-incompatible kidney transplantation in the United Kingdom. Transfusion 2016; 56:2668.</a></li><li><a class="nounderline abstract_t">Becker LE, Siebert D, Süsal C, et al. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation 2015; 99:2364.</a></li><li><a class="nounderline abstract_t">Squifflet JP, De Meyer M, Malaise J, et al. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2004; 2:208.</a></li><li><a class="nounderline abstract_t">Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation 2014; 98:794.</a></li><li><a class="nounderline abstract_t">Lo P, Sharma A, Craig JC, et al. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2016; 100:933.</a></li><li><a class="nounderline abstract_t">Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22:447.</a></li><li><a class="nounderline abstract_t">Sasaki H, Hotta K, Mitsuke A, et al. Long-Term Outcome of ABO-Incompatible Kidney Transplantation in Patients Treated With Low-Dose Rituximab Regimen. Transplant Proc 2021; 53:989.</a></li><li><a class="nounderline abstract_t">Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12:469.</a></li><li><a class="nounderline abstract_t">Lee HR, Kim K, Lee SW, et al. Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis. Medicine (Baltimore) 2021; 100:e24853.</a></li><li><a class="nounderline abstract_t">Segev DL, Simpkins CE, Warren DS, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5:2570.</a></li><li><a class="nounderline abstract_t">Ishida H, Kondo T, Shimizu T, et al. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation. Transpl Int 2015; 28:286.</a></li><li><a class="nounderline abstract_t">Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3:952.</a></li><li><a class="nounderline abstract_t">Onitsuka S, Yamaguchi Y, Tanabe K, et al. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999; 13 Suppl 1:33.</a></li><li><a class="nounderline abstract_t">Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829.</a></li><li><a class="nounderline abstract_t">Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86.</a></li><li><a class="nounderline abstract_t">Bentall A, Herrera LP, Cornell LD, et al. Differences in chronic intragraft inflammation between positive crossmatch and ABO-incompatible kidney transplantation. Transplantation 2014; 98:1089.</a></li><li><a class="nounderline abstract_t">Scurt FG, Ewert L, Mertens PR, et al. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet 2019; 393:2059.</a></li><li><a class="nounderline abstract_t">de Weerd AE, Betjes MGH. ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis. Clin J Am Soc Nephrol 2018; 13:1234.</a></li><li><a class="nounderline abstract_t">Padmanabhan A, Ratner LE, Jhang JS, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation 2009; 87:1889.</a></li><li><a class="nounderline abstract_t">Axelrod D, Segev DL, Xiao H, et al. Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients. Am J Transplant 2016; 16:1465.</a></li><li><a class="nounderline abstract_t">Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25:3778.</a></li><li><a class="nounderline abstract_t">Schaefer B, Tönshoff B, Schmidt J, et al. Bleeding complications in pediatric ABO-incompatible kidney transplantation. Pediatr Nephrol 2013; 28:327.</a></li><li><a class="nounderline abstract_t">Hwang JK, Kim YK, Kim JM, et al. Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea. Transplant Proc 2013; 45:2931.</a></li><li><a class="nounderline abstract_t">de Weerd AE, van Agteren M, Leebeek FW, et al. ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transpl Int 2015; 28:25.</a></li><li><a class="nounderline abstract_t">Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. Nephrol Dial Transplant 2011; 26:4124.</a></li><li><a class="nounderline abstract_t">Haidinger M, Schmaldienst S, Körmöczi G, et al. Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr 2009; 121:247.</a></li><li><a class="nounderline abstract_t">Lopau K, Syamken K, Rubenwolf P, et al. Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantation. Kidney Blood Press Res 2010; 33:52.</a></li><li><a class="nounderline abstract_t">Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320.</a></li><li><a class="nounderline abstract_t">Hall EC, Engels EA, Montgomery RA, Segev DL. Cancer risk after ABO-incompatible living-donor kidney transplantation. Transplantation 2013; 96:476.</a></li><li><a class="nounderline abstract_t">Opelz G, Morath C, Süsal C, et al. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation 2015; 99:400.</a></li></ol></div><div id="topicVersionRevision">Topic 113661 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14067508" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : RENAL HOMOTRANSPLANTATION IN MAN IN MODIFIED RECIPIENTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3327640" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ABO blood group incompatible kidney transplantation: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458019" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term results of ABO-incompatible living kidney transplantation: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14628736" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multicentre trial of ABO-incompatible kidney transplantation. Japanese Biosynsorb ABO-incompatible kidney transplant study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33041078" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term Follow-up of ABO-Incompatible Kidney Transplantation in Freiburg, Germany: A Single-Center Outcome Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry Committee, Japanese Society for Clinical Renal Transplantation and the Japan Society for Transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290268" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Outcomes of ABO-incompatible kidney transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35266618" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : OPTN/SRTR 2020 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935372" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523889" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750423" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371661" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458025" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ten-year experience in transplantation of A2 kidneys into B and O recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12102266" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transplantation of ABO group A2 kidneys from living donors into group O and B recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003236" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Improving access to kidney transplantation without decreasing graft survival: long-term outcomes of blood group A2/A2B deceased donor kidneys in B recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913566" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A2 incompatible kidney transplantation does not adversely affect graft or patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20420632" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623808" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162980" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906036" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260836" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367217" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Donor kidney exchanges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095513" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Dutch national living donor kidney exchange program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104403" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early experience of paired living kidney donation in the United kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848501" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The 6-year clinical outcomes for patients registered in a multiregional United States Kidney Paired Donation program - a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437286" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney exchange match rates in a large multicenter clearinghouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063811" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Temporal changes in the composition of a large multicenter kidney exchange clearinghouse: Do the hard-to-match accumulate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926599" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The structural basis of blood group A-related glycolipids in an A3 red cell phenotype and a potential explanation to a serological phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36732087" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ABO Genotyping finds more A2 to B kidney transplant opportunities than lectin-based subtyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547818" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Blood group ABO-incompatible kidney transplantation biochemical and immunochemical studies of blood group A glycolipid antigens in human kidney and characterization of the antibody response (antigen specificity and antibody class) in O recipients receiving A2 grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12698082" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360584" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Renal transplantation across the ABO barrier using A2 kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20354481" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Transplantation of A2 kidneys into B and O recipients leads to reduction in waiting time: USRDS experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704145" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704145" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659826" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transplantation of ABO A2 kidneys into O recipients: do IgM anti-A1 titers matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372745" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : First Report on the OPTN National Variance: Allocation of A2 /A2 B Deceased Donor Kidneys to Blood Group B Increases Minority Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678040" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33521251" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Safe Anti-A2 Titer for a Successful A2 Incompatible Kidney Transplantation: A Single-center Experience and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384174" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : ABO incompatible renal transplantation: a paradigm ready for broad implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382504" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24188566" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389083" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24978035" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397806" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913485" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833910" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31837028" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892322" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Human ABO-incompatible living donor renal homografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3321614" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Present experiences in a series of 26 ABO-incompatible living donor renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972229" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371928" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297552" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912420" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ABO-incompatible renal transplantation without antibody removal using conventional immunosuppression alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21449947" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496528" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26610596" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21558429" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25340594" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient: The Swiss Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27562458" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical outcomes with ABO antibody titer variability in a multicenter study of ABO-incompatible kidney transplantation in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989497" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15859930" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321163" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A systematic review of the use of rituximab for desensitization in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26425876" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144092" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33272650" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-Term Outcome of ABO-Incompatible Kidney Transplantation in Patients Treated With Low-Dose Rituximab Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22054413" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33725841" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162210" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25363583" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859529" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751054" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889542" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021283" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911035" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Differences in chronic intragraft inflammation between positive crossmatch and ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006573" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30012630" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543070" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603690" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466677" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22961637" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bleeding complications in pediatric ABO-incompatible kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157006" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070762" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21622990" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19562281" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vienna experience of ABO-incompatible living-donor kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20197687" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626962" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799426" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cancer risk after ABO-incompatible living-donor kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25050471" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
